HeartSciences is a medical technology company focused on applying innovative AI-based technology to ECGs to expand and improve ECG clinical utility. Millions of ECGs are performed every week.
HeartSciences objective is to improve healthcare by making it a far more valuable ECG, particularly in frontline or point-of-care clinical settings.
HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patients’ care and lead to better outcomes.
HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG™, is a resting 12-lead ECG designed to deliver diagnostic insights on cardiac dysfunction, traditionally only available through advanced cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.
Chairman and CEO / Board Member
Chief Operating Officer / Board Member
Chief Financial Officer
VP Research and Development
Chairman and CEO / Board Member
Chief Operating Officer / Board Member
Board Member
Board Member
Board Member
HeartSciences’ AI-ECG products are currently in development and not commercially available in the United States.
wavECG and wavEKG are trademarks of HeartSciences.
MV-WBSTE-002 Rev A
MD, MBBS, FACC
Dr. Partho P. Sengupta, MD, MBBS, FACC, is the Henry Rutgers Professor and the Chief of Division of Cardiology at Rutgers Robert Wood Johnson Medical School and the Robert Wood Johnson University Hospital. Dr Sengupta completed his clinical residency and cardiology fellowship from Mayo Clinic Rochester and Arizona in 2007 and 2010 respectively. He has over 250 peer-reviewed publications. He is an Associate Editor for the Journal of American College of Cardiology for Cardiovascular Imaging, has served as a Board of Director for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce. Prior to his role at Rutgers, he served as Abnash C Jain Chair and Professor of Cardiology, Chief of Division of Cardiology and Director of Cardiac Imaging at West Virginia University, Morgantown.
He has won several excellence awards with the most recent being the ASE’s Rich Popp Award for Excellence in Teaching in 2020. Other significant awards include the AACIO Young Investigator Award in 2010, Mayo Brother’s Distinguished Fellowship Award in 2009, Mayo Clinic Research Award in 2007, ASE’s Young Investigator Award in 2004, among others.
With his futuristic ideas, investigative skills and international work, Dr. Sengupta is widely acclaimed by major media outlets. He delivered ASE’s first-ever presentation using hologram technology at the ASE’s 24th Annual Scientific Sessions in 2018. He was nominated by the American Medical Association for the “Inspiration in Medicine” talk,2017. In 2016, he was invited as stage speaker for TEDMED where he presented on “Using Holography to Reshape Cardiology”. He also received the ASE’s 14th Feigenbaum Lectureship for his significant contributions to research in the field of echocardiography in 2013.
MD,MSc
Dr. Jordan Strom is Assistant Professor of Medicine at Harvard Medical School, Director of the Echocardiography Laboratory, and Director of Echocardiographic Research at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and Section Head for Cardiovascular Imaging Research at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology. His research which has been funded by the NIH and American Heart Association involves evaluation of the relationship of cardiac structure and function to health outcomes and the optimal use and timing of cardiac imaging in practice. He has published more than 70 papers in peer-reviewed journals, is a member of the Editorial Board of the Journal of the American Society of Echocardiography, and serves as Guest Editor for the Journal of the American Society of Echocardiography and the Journal of Cardiovascular Magnetic Resonance. He additionally was the inaugural American Society of Echocardiography (ASE) leadership academy member elected to the Board of Directors of the ASE and previously served on the American College of Cardiology Imaging Council Leadership Committee. He currently serves on the Board of Directors of the International Contrast Ultrasound Society, and is the current American College of Cardiology representative to the Board of Directors of the Joint Review Committee on Education in Diagnostic Medical Sonography, which accredits sonography training programs in the United States. Additionally, he is the American College of Cardiology Commissioner to CAAHEP, the largest accreditor of allied health professions in the United States.
Ph.D.
Benjamin Glicksberg, PhD is an Assistant Professor of Genetics and Genomic Sciences and a member of the Hasso Plattner Institute for Digital Health at the Icahn School of Medicine at Mount Sinai. Dr. Glicksberg has extensive experience in clinical informatics and work involving Electronic Health Record data. He uses machine learning to couple multi-omic patient health data to forward personalized medicine. He completed his PhD in Neuroscience at the Icahn School of Medicine at Mount Sinai in 2017 and post-doctoral work at the University of California, San Francisco in 2019.
Board Member
Since May 2020, Bruce Bent has served as a director of our Company. Mr. Bent has more than 35 years of experience in financial management. From September 2014 to February 2022, Mr. Bent has served as Chairman of Net Zero Renewable Energy Inc. (fka Enerdynamic Hybrid Technologies Corp.). In addition, since March 2018, Mr. Bent has served as Chairman for Astro Aerospace Ltd., an OTC listed public company. From June 2020 to January 2024, Mr. Bent has been Vice President and Chief Financial Officer Emeritus of The Matthews Group, referred to in this section as Matthews, and, from August 2004 to June 2020, he served as the Chief Financial Officer of Matthews as well as president of various Canadian subsidiaries of Matthews. Mr. Bent retired from Matthews in January 2024. Matthews is a $500M real estate development company. During his tenure with Matthews, among other projects, Mr. Bent was integral in the completion of a $1.7 billion dollar corporate headquarters building for Encana (now Ovintiv Inv., NYSE: OVV). Since April 2000, Mr. Bent has served as president of MSW Investments Limited, a family office providing early stage financing. Mr. Bent graduated from the University of Manitoba with a Bachelor of Commerce (honors) and obtained his Chartered Professional Accounting designation from the Province of Ontario.
Board Member
Since December 2022, David R. Wells, has served as a director of our Company. Mr. Wells is the Chief Financial Officer of Envoy Medical, Inc., a publicly traded medical device company in the hearing health space, a position he began in August, 2023. Also, Mr. Wells is a partner of Atlas Bookkeeping, LLC, a technology based financial services firm providing bookkeeping and reporting for emerging growth and small cap public and privately held companies, which he founded in October 2022. Prior to that, Mr. Wells served as the Chief Financial Officer of GHS Investments, LLC, a privately held “super value” fund focused on small to mid-cap companies, from June 2021 to September 2022, and served as the Chief Financial Officer of ENDRA Life Sciences Inc., a publicly traded clinical diagnostics technology company, initially on an interim basis beginning in May 2014, and on a continuing basis beginning in 2017 until June 2021. Mr. Wells was the founder of Wells Compliance Group, a technology-based services firm supporting the financial reporting needs of publicly traded companies and privately held firms whose investor or shareholder base required timely GAAP-compliant financial reporting. During his time at StoryCorp Consulting, Inc. (d/b/a/ Wells Compliance Group) from September 2009 to June 2021, Mr. Wells consulted with several emerging growth publicly traded companies. He possesses over 30 years of experience in finance, operations and administrative positions. Mr. Wells holds an MBA from Pepperdine University and a BS in Finance and Entrepreneurship from Seattle Pacific University.
With a diverse background spanning regulatory affairs, clinical trial design and management, product management, and quality assurance, Isabella has a unique blend of expertise to drive success for any medtech program. She has guided regulatory, quality, and clinical initiatives for over 100 successful regulatory filings and FDA interactions. She has also authored articles for multiple publications, participated in numerous podcasts, and engaged in speaking opportunities covering regulatory affairs submissions and interactions for medical devices and AI/ML in healthcare. As a member of the AAMI/ISO Standards working group, she also helped to establish Application Of ISO 14971 To Machine Learning In Artificial Intelligence. She has a RAC Certification, Master’s in Business Administration, and a Bachelor’s of Science in Chemistry and has won awards for success in business, including the Stevie’s Business Award as well as Houston Business Journal’s Award for Women to Watch.
Board Member
Since 2014, Brian Szymczak, has served as a director of our Company. Mr. Szymczak is currently the principal of The Law Office of Brian Szymczak PLLC where he specializes in providing legal counsel to medical technology clients. Mr. Szymczak previously led the legal and compliance functions for Apollo Endosurgery, Inc., referred to in this section as Apollo, in Austin, Texas where he served as Vice President of Legal and Compliance until Apollo’s acquisition in 2023 by Boston Scientific. In this role, Mr. Szymczak managed legal disputes and litigation matters and provided general legal counsel to the company’s leadership, sales, operations, research and development, and human resources groups. Prior to working at Apollo, from 2006 to 2014, Mr. Szymczak served in various roles including as Associate General Counsel and Director of Legal Affairs for a medical device manufacturer and from, 1999 to 2006, worked as an associate at the law firm of Baker Botts, LLP where he counseled clients on patent and other intellectual property matters in a variety of industries. Mr. Szymczak is a 1999 graduate of Duke University School of Law and holds a Bachelor of Science in Mechanical Engineering from Texas A&M University.
VP Research and Development
Aaron is a highly experienced technical professional and leader in the Medical Device industry. He has nearly 25 years of Engineering, Product Development, and Management experience at some of the most reputable Medical Device companies such as St. Jude Medical, Boston Scientific, and Guidant. Aaron has successfully productized multiple innovative technologies from concept through production in the areas of Cardiac Rhythm Management and Neuromodulation. Many of these innovations enabled the introduction of new products to a somewhat commoditized market, resulting in significant sales growth for the business as well as overall growth in the market. Aaron is co-author on multiple patents and has received various technical awards throughout his career. Aaron is also an active influencer in the Medical Device industry and is a member of the Board of Trustees for the International Society of Computerized Electrocardiography.
Chief Financial Officer
Since April 2022, Danielle Watson has served as our Chief Financial Officer. Prior to her appointment to Chief Financial Officer, Ms. Watson, a CPA, served as the Company’s Financial Controller since November 2021. Ms. Watson brings over 17 years of financial experience to her role. Before joining the Company, Ms. Watson held senior leadership roles at Moss Adams, LLP from November 2007 to November 2021 where she provided audit and assurance services to both public and privately held companies with an emphasis in financial reporting, consolidations, strategic planning, purchase price accounting, and SEC reporting. Ms. Watson earned her Bachelor of Science, with a double concentration in accounting and finance from Texas Christian University and her Master of Science in accounting from the University of Texas at Arlington and is an active Certified Public Accountant in Texas
Chief Operating Officer / Board Member
Since March 2022, Mark Hilz has served as our Chief Operating Officer and Secretary and, since June 2013, has also been a director of our Company. Mr. Hilz served as the Chief Executive Officer of the Company from June 2013 until March 2022. Mr. Hilz has over 30 years of experience as a President and/or CEO of multiple startup companies. He was previously CEO of INX Inc., a technology infrastructure consulting company. INX Inc. started in 2000 and grew to $400 million in revenue. INX Inc. was traded on Nasdaq, completed multiple offerings until it was acquired in December 2011. Prior to that, Mr. Hilz founded and was CEO of a technology logistics outsourcing firm, PC Service Source Inc., that grew to over $160 million in revenue. Mr. Hilz raised the startup capital from traditional venture capital sources and after four years of operations took PC Service Source Inc. public in an initial public offering as a Nasdaq global listed company. Mr. Hilz’s experience includes raising venture capital as well as multiple successful public offerings and numerous merger and acquisition transactions as both a buyer and a seller.
Chairman and CEO / Board Member
Since March 2022, Andrew Simpson has served as our President and Chief Executive Officer. Mr. Simpson has also served as the Chairman of our Board of Directors, since June 2013, and as a director of our Company since July 2012. Mr. Simpson has over 30 years’ experience across a variety of business sectors and sizes. He was Group CEO of The Peel Group from 2006 to 2010, which is a large private company in the UK which, at the time, had approximately $8 billion of business assets across the real estate, ports, airports, energy, media, telecoms and environmental sectors. He was a main board director of Speedy Hire plc from 2003 to 2006 (during which time it became a FTSE 250 company) and during his tenure was Managing Director of its Equipment Rental division which had revenues of approximately $200 million and was also responsible for the Group’s development and expansion which included seventeen acquisitions and several non-core divestments. Mr. Simpson qualified as a Chartered Accountant with Price Waterhouse and spent eight years working in investment banking at Rothschild, advising on a wide variety of merger and acquisition transactions, debt and equity fundraisings, IPOs and other advisory assignments. Mr. Simpson graduated with first class honors in 1991 from Sheffield Hallam University in the UK where he received a Bachelor of Arts (honors) in Accounting and Management Control.
